JPH09505033A - ホスホイノシチド特異的ホスホリパーゼｃの阻害剤 - Google Patents

ホスホイノシチド特異的ホスホリパーゼｃの阻害剤

Info

Publication number
JPH09505033A
JPH09505033A JP7511980A JP51198095A JPH09505033A JP H09505033 A JPH09505033 A JP H09505033A JP 7511980 A JP7511980 A JP 7511980A JP 51198095 A JP51198095 A JP 51198095A JP H09505033 A JPH09505033 A JP H09505033A
Authority
JP
Japan
Prior art keywords
hydrogen
plc
human mammal
need
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7511980A
Other languages
English (en)
Japanese (ja)
Inventor
ギブス，ジヤクソン・ビー
コブラン，ケネス・エス
マクラウド，アンガス・エム
マーチヤント，ケビン・ジエイ
Original Assignee
メルク エンド カンパニー インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク エンド カンパニー インコーポレーテッド filed Critical メルク エンド カンパニー インコーポレーテッド
Publication of JPH09505033A publication Critical patent/JPH09505033A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP7511980A 1993-10-15 1994-10-11 ホスホイノシチド特異的ホスホリパーゼｃの阻害剤 Pending JPH09505033A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/138,133 US5519163A (en) 1993-10-15 1993-10-15 Inhibitors of phosphoinositide-specific phospholipase C
US138,133 1993-10-15
PCT/US1994/011497 WO1995010286A1 (en) 1993-10-15 1994-10-11 Inhibitors of phosphoinositide-specific phospholipase c

Publications (1)

Publication Number Publication Date
JPH09505033A true JPH09505033A (ja) 1997-05-20

Family

ID=22480566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7511980A Pending JPH09505033A (ja) 1993-10-15 1994-10-11 ホスホイノシチド特異的ホスホリパーゼｃの阻害剤

Country Status (6)

Country Link
US (1) US5519163A (enExample)
EP (1) EP0746323A1 (enExample)
JP (1) JPH09505033A (enExample)
AU (1) AU696622B2 (enExample)
CA (1) CA2173456A1 (enExample)
WO (1) WO1995010286A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011140492A (ja) * 2004-02-20 2011-07-21 Sanofi-Aventis Deutschland Gmbh グリメピリド誘導及びインスリン誘導グリコシルホスファチジルイノシトール特異的ホスホリパーゼｃ制御

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002224354A1 (en) 2000-10-10 2002-04-22 University Of North Carolina At Chapel Hill Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
WO2003094852A2 (en) * 2002-05-11 2003-11-20 Ilex Products, Inc. Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators
EP2428516A1 (en) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
EP1896039A2 (en) * 2005-06-07 2008-03-12 The Regents of the University of California Inhibition of epac, phospholipase c ''epsilon'', and phospholipase d to treat pain
WO2013138684A1 (en) 2012-03-15 2013-09-19 Montana Molecular Llc Genetically encoded fluorescent sensors for detecting intracellular signalling through diacylglycerol pathways
EP3738971B1 (en) 2013-11-04 2024-07-17 Montana Molecular LLC Genetically encoded fluorescent sensors for detecting ligand bias and intracellular signaling through camp pathways
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
CN109516623B (zh) * 2018-11-16 2021-06-01 浙江万盛股份有限公司 一种三丁氧乙基磷酸酯废水的综合利用方法
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011140492A (ja) * 2004-02-20 2011-07-21 Sanofi-Aventis Deutschland Gmbh グリメピリド誘導及びインスリン誘導グリコシルホスファチジルイノシトール特異的ホスホリパーゼｃ制御

Also Published As

Publication number Publication date
EP0746323A4 (enExample) 1997-01-22
AU696622B2 (en) 1998-09-17
WO1995010286A1 (en) 1995-04-20
CA2173456A1 (en) 1995-04-20
AU7973894A (en) 1995-05-04
EP0746323A1 (en) 1996-12-11
US5519163A (en) 1996-05-21

Similar Documents

Publication Publication Date Title
JP4102445B2 (ja) 脂肪酸アミドヒドロラーゼ
JP3759941B2 (ja) 血小板活性化因子アセチルヒドロラーゼ
US5519163A (en) Inhibitors of phosphoinositide-specific phospholipase C
KR19990035870A (ko) 엔-(아로일)글리신 하이드록삼산 유도체 및 이와 관련된 화합물
JP2757987B2 (ja) ヒト抗‐炎症ホスホリパーゼ阻害蛋白
EP0793721B1 (fr) Peptides capables de se lier au domaine sh3 de la proteine gap, sequences nucleotidiques codant pour ces peptides, leur preparation et utilisation
JP3054092B2 (ja) 滑膜ホスホリパーゼ抗体
JPH10501969A (ja) ５−リポキシゲナーゼ活性化タンパク質ｉｉ
WO2006011485A1 (ja) アミロイドペプチドの凝集を抑制する蛋白質とその作用
US5955305A (en) Human retinoid binding protein
US6107472A (en) Receptor-type tyrosine kinase-like molecules
US5831052A (en) New human translocation associated protein
JPH0751065A (ja) 糖タンパク質３９遺伝子
US5474921A (en) Expression and purification of phosphoinositide-specific phospholipase C-γ
JPH10201487A (ja) 哺乳動物のｆｉｎ−１核酸および蛋白質配列およびその使用
JP4034381B2 (ja) γ−グルタミルトランスペプチターゼの新規な用途
US5990294A (en) Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene, and methods of use thereof
US5523391A (en) DNA fragment encoding tumor cell growth inhibitors
JPWO2003031615A1 (ja) リゾホスファチジン酸合成酵素阻害物質
US20040126858A1 (en) Novel polypeptide-nadp dependent leukotriene b412-hydroxydehydrogenase-36 and the polynucleotide encoding said polypeptide
US20020173002A1 (en) Human retinoid binding protein
WO2009030088A1 (fr) Fonction et utilisation d'un nouvel inhibiteur de la protéine kinase ii humaine dépendant du calcium/de la calmoduline
WO2000007614A1 (fr) Remèdes contre les maladies de dégénérescence nerveuse
WO2001021775A1 (en) Gene encoding novel human secretory phospholipase a¿2?
CN1342713A (zh) 人长寿保障蛋白和编码序列及其用途